Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Oxford BioMedica

DB:OXOA
Snowflake Description

Flawless balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OXOA
DB
£419M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson’s disease, central nervous system disorders, and ophthalmology in Europe and internationally. The last earnings update was 214 days ago. More info.


Add to Portfolio Compare Print
  • Oxford BioMedica has significant price volatility in the past 3 months.
OXOA Share Price and Events
7 Day Returns
-0.8%
DB:OXOA
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-30.2%
DB:OXOA
-13.2%
DE Biotechs
-20.9%
DE Market
OXOA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Oxford BioMedica (OXOA) -0.8% -11.4% -23.5% -30.2% 189% -35.9%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • OXOA underperformed the Biotechs industry which returned -13.2% over the past year.
  • OXOA underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
OXOA
Industry
5yr Volatility vs Market
Related Companies

OXOA Value

 Is Oxford BioMedica undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Oxford BioMedica to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Oxford BioMedica.

DB:OXOA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 6 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:OXOA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 6.1%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 19%) (2.02%))
1.139
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.139 * 6.07%)
6.52%

Discounted Cash Flow Calculation for DB:OXOA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Oxford BioMedica is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:OXOA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 6.52%)
2020 0.39 Analyst x1 0.37
2021 13.23 Analyst x1 11.66
2022 24.09 Est @ 82.09% 19.93
2023 37.91 Est @ 57.35% 29.44
2024 53.08 Est @ 40.03% 38.70
2025 67.89 Est @ 27.9% 46.47
2026 81.07 Est @ 19.41% 52.09
2027 91.99 Est @ 13.47% 55.49
2028 100.56 Est @ 9.31% 56.94
2029 107.00 Est @ 6.4% 56.88
Present value of next 10 years cash flows £367.00
DB:OXOA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= £107.00 × (1 + -0.39%) ÷ (6.52% – -0.39%)
£1,541.75
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £1,541.75 ÷ (1 + 6.52%)10
£819.55
DB:OXOA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £367.00 + £819.55
£1,186.55
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £1,186.55 / 76.91
£15.43
DB:OXOA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:OXOA represents 1.08716x of LSE:OXB
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.08716x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (GBP) x Listing Adjustment Factor
= £ 15.43 x 1.08716
€16.77
Value per share (EUR) From above. €16.77
Current discount Discount to share price of €5.93
= -1 x (€5.93 - €16.77) / €16.77
64.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Oxford BioMedica is available for.
Intrinsic value
>50%
Share price is €5.93 vs Future cash flow value of €16.77
Current Discount Checks
For Oxford BioMedica to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Oxford BioMedica's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Oxford BioMedica's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Oxford BioMedica's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Oxford BioMedica's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:OXOA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in GBP £-0.12
LSE:OXB Share Price ** LSE (2020-04-03) in GBP £5.45
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Oxford BioMedica.

DB:OXOA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= LSE:OXB Share Price ÷ EPS (both in GBP)

= 5.45 ÷ -0.12

-46.97x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oxford BioMedica is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Oxford BioMedica is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Oxford BioMedica's expected growth come at a high price?
Raw Data
DB:OXOA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -46.97x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-5.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Oxford BioMedica, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Oxford BioMedica's assets?
Raw Data
DB:OXOA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in GBP £1.04
LSE:OXB Share Price * LSE (2020-04-03) in GBP £5.45
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:OXOA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= LSE:OXB Share Price ÷ Book Value per Share (both in GBP)

= 5.45 ÷ 1.04

5.22x

* Primary Listing of Oxford BioMedica.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oxford BioMedica is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Oxford BioMedica's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Oxford BioMedica has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

OXOA Future Performance

 How is Oxford BioMedica expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-5.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Oxford BioMedica expected to grow at an attractive rate?
  • Unable to compare Oxford BioMedica's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Oxford BioMedica's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Oxford BioMedica's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:OXOA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:OXOA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -5.8%
DB:OXOA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 17.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:OXOA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:OXOA Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 131 -10 1
2022-12-31 131 44 -16 2
2021-12-31 111 21 -9 5
2020-12-31 95 14 -1 6
2020-04-05
2019-12-31 73 4 -12 6
DB:OXOA Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-06-30 64 -4 -8
2019-03-31 65 4 0
2018-12-31 67 13 8
2018-09-30 62 18 4
2018-06-30 57 23 0
2018-03-31 47 13 -5
2017-12-31 38 3 -9
2017-09-30 34 -1 -10
2017-06-30 31 -6 -11
2017-03-31 29 -4 -14
2016-12-31 28 -2 -17
2016-09-30 26 -1 -16

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Oxford BioMedica is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Oxford BioMedica's revenue is expected to grow by 17.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:OXOA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Oxford BioMedica Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OXOA Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.14 -0.14 -0.14 1.00
2022-12-31 -0.20 -0.20 -0.20 1.00
2021-12-31 -0.19 -0.08 -0.29 2.00
2020-12-31 -0.02 0.07 -0.07 4.00
2020-04-05
2019-12-31 -0.17 -0.09 -0.27 4.00
DB:OXOA Past Financials Data
Date (Data in GBP Millions) EPS *
2019-06-30 -0.12
2019-03-31 0.00
2018-12-31 0.12
2018-09-30 0.05
2018-06-30 -0.01
2018-03-31 -0.08
2017-12-31 -0.15
2017-09-30 -0.16
2017-06-30 -0.18
2017-03-31 -0.24
2016-12-31 -0.30
2016-09-30 -0.31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Oxford BioMedica will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Oxford BioMedica's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Oxford BioMedica has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

OXOA Past Performance

  How has Oxford BioMedica performed over the past 5 years?

  • Oxford BioMedica's last earnings update was 214 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Oxford BioMedica's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Oxford BioMedica does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Oxford BioMedica's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Oxford BioMedica's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Oxford BioMedica's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Oxford BioMedica Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:OXOA Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 63.59 -7.81 9.03 33.90
2019-03-31 65.19 -0.13 8.23 31.81
2018-12-31 66.78 7.54 7.43 29.71
2018-09-30 61.98 3.52 7.29 27.46
2018-06-30 57.18 -0.49 7.14 24.55
2018-03-31 47.39 -4.76 7.21 23.08
2017-12-31 37.59 -9.02 7.28 21.61
2017-09-30 34.29 -9.81 6.21 21.83
2017-06-30 30.99 -10.60 5.15 22.05
2017-03-31 29.38 -13.62 5.55 23.17
2016-12-31 27.78 -16.64 5.96 24.30
2016-09-30 25.89 -16.46 6.78 24.06
2016-06-30 24.01 -16.28 7.61 23.81
2016-03-31 19.96 -14.65 7.17 22.04
2015-12-31 15.91 -13.02 6.74 20.27
2015-09-30 14.59 -11.50 5.69 19.80
2015-06-30 13.27 -9.99 4.64 19.33
2015-03-31 13.45 -9.32 4.30 18.16
2014-12-31 13.62 -8.66 3.96 16.99
2014-09-30 10.80 -9.35 3.63 15.37
2014-06-30 7.99 -10.04 3.30 13.76
2014-03-31 6.68 -10.57 3.36 13.76
2013-12-31 5.38 -11.10 3.42 13.75
2013-09-30 5.40 -10.37 3.09 13.84
2013-06-30 5.43 -9.64 2.76 13.93

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Oxford BioMedica has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • Oxford BioMedica used its assets less efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • It is difficult to establish if Oxford BioMedica improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Oxford BioMedica's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Oxford BioMedica has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

OXOA Health

 How is Oxford BioMedica's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Oxford BioMedica's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Oxford BioMedica is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Oxford BioMedica's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Oxford BioMedica's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Oxford BioMedica has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Oxford BioMedica Company Filings, last reported 9 months ago.

DB:OXOA Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 80.20 0.00 26.07
2019-03-31 80.20 0.00 26.07
2018-12-31 34.74 41.15 32.24
2018-09-30 34.74 41.15 32.24
2018-06-30 31.29 38.84 43.97
2018-03-31 31.29 38.84 43.97
2017-12-31 6.15 36.86 14.33
2017-09-30 6.15 36.86 14.33
2017-06-30 10.80 33.87 10.18
2017-03-31 10.80 33.87 10.18
2016-12-31 12.62 34.39 15.34
2016-09-30 12.62 34.39 15.34
2016-06-30 9.28 31.32 11.91
2016-03-31 9.28 31.32 11.91
2015-12-31 10.89 27.26 9.36
2015-09-30 10.89 27.26 9.36
2015-06-30 17.26 15.69 15.12
2015-03-31 17.26 15.69 15.12
2014-12-31 23.04 1.00 14.20
2014-09-30 23.04 1.00 14.20
2014-06-30 24.30 1.00 18.25
2014-03-31 24.30 1.00 18.25
2013-12-31 8.90 0.00 2.17
2013-09-30 8.90 0.00 2.17
2013-06-30 14.02 0.00 6.85
  • Oxford BioMedica has no debt.
  • Oxford BioMedica has no debt compared to 5 years ago when it was 4.1%.
  • Oxford BioMedica has no debt, it does not need to be covered by operating cash flow.
  • Oxford BioMedica has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Oxford BioMedica's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Oxford BioMedica has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

OXOA Dividends

 What is Oxford BioMedica's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Oxford BioMedica dividends. Estimated to be 0% next year.
If you bought €2,000 of Oxford BioMedica shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Oxford BioMedica's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Oxford BioMedica's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:OXOA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:OXOA Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 3.00
2020-12-31 0.00 3.00
2020-04-05
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Oxford BioMedica has not reported any payouts.
  • Unable to verify if Oxford BioMedica's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Oxford BioMedica's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Oxford BioMedica has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Oxford BioMedica's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Oxford BioMedica's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Oxford BioMedica afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Oxford BioMedica has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

OXOA Management

 What is the CEO of Oxford BioMedica's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
John Dawson
COMPENSATION £1,311,000
AGE 59
TENURE AS CEO 11.5 years
CEO Bio

Mr. John Dawson has been the Chief Executive Officer of Oxford BioMedica PLC since October 13, 2008. Mr. Dawson has broad experience in European commercial activities, finance and in mergers and acquisitions in the region. He is an experienced Pharmaceutical Business Leader with extensive experience in the business development arena. Mr. Dawson served as an Acting Chief Executive Officer at Oxford BioMedica PLC, from August 28, 2008 to October 13, 2008. He served as Chief Financial Officer and Head of Business Development of Cephalon Europe at Cephalon Inc. since February 14, 2005. Mr. Dawson held senior management positions in the European operations of Cephalon Inc. from 1996 to 2007, including from 2005, a management board position as the Chief Financial Officer and Head of Business Development Europe. He was involved significantly in structuring and negotiating Cephalon's European acquisitions and was responsible for launching its products in several European markets. In his time at Cephalon, He was instrumental in the many deals that built the European business to over 1,000 people, taking the business from having no sales in 1998 to a turnover of several hundred million US dollars. In 2005 he led the $360 million acquisition of Zeneus by Cephalon. He has been a Non Executive Director of Oxford BioMedica PLC since August 2008. Mr. Dawson serves as Member of Advisory Panel at Par Equity LLP. He has a B.Sc from the University of Swansea, a Diploma in Marketing and a Membership of Institute of Marketing and is a Member of the Institute of Chartered Accountants.

CEO Compensation
  • John's compensation has increased whilst company is loss making.
  • John's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Oxford BioMedica management team in years:

2
Average Tenure
59
Average Age
  • The tenure for the Oxford BioMedica management team is about average.
Management Team

John Dawson

TITLE
CEO & Executive Director
COMPENSATION
£1M
AGE
59
TENURE
11.5 yrs

Stuart Paynter

TITLE
CFO, Company Secretary & Director
COMPENSATION
£501K
AGE
46
TENURE
2.7 yrs

Peter Nolan

TITLE
Consultant
COMPENSATION
£520K
AGE
66
TENURE
1.8 yrs

Nick Page

TITLE
Chief Operations Officer
TENURE
2 yrs

James Miskin

TITLE
Chief Technical Officer

Kyriacos Mitrophanous

TITLE
Chief Scientific Officer

Catherine Isted

TITLE
Head of Corporate Development & IR

Natalie Walter

TITLE
General Counsel
TENURE
0.9 yrs

Sarah Macleod

TITLE
Head of Communications

Helen Stephenson-Ellis

TITLE
Chief People Officer
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the Oxford BioMedica board of directors in years:

4.2
Average Tenure
59
Average Age
  • The tenure for the Oxford BioMedica board of directors is about average.
Board of Directors

Lorenzo Tallarigo

TITLE
Non-Executive Chairman
COMPENSATION
£150K
AGE
68
TENURE
4.2 yrs

John Dawson

TITLE
CEO & Executive Director
COMPENSATION
£1M
AGE
59
TENURE
11.7 yrs

Andrew John Heath

TITLE
Deputy Chairman & Senior Independent Director
COMPENSATION
£65K
AGE
71
TENURE
8.9 yrs

Stuart Paynter

TITLE
CFO, Company Secretary & Director
COMPENSATION
£501K
AGE
46
TENURE
2.7 yrs

Stuart Henderson

TITLE
Independent Non-Executive Director
COMPENSATION
£65K
AGE
60
TENURE
3.8 yrs

William Langston

TITLE
Member of Scientific Advisory Board

Peter Stern

TITLE
Member of Scientific Advisory Board

Krystof Bankiewicz

TITLE
Member of Scientific Advisory Board

Martin Diggle

TITLE
Non-Executive Director
AGE
56
TENURE
7.5 yrs

Heather Preston

TITLE
Independent Non-Executive Director
COMPENSATION
£52K
AGE
53
TENURE
2.1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Oxford BioMedica individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
25. Mar 20 Buy Lorenzo Tallarigo Individual 25. Mar 20 25. Mar 20 482 €6.04 €2,912
20. Mar 20 Buy Vulpes Investment Management Private Ltd Company 18. Mar 20 18. Mar 20 7,378 €4.16 €30,672
26. Feb 20 Buy Lorenzo Tallarigo Individual 26. Feb 20 26. Feb 20 438 €7.25 €3,175
03. Feb 20 Buy Lorenzo Tallarigo Individual 31. Jan 20 31. Jan 20 445 €7.15 €3,182
19. Dec 19 Buy Lorenzo Tallarigo Individual 19. Dec 19 19. Dec 19 415 €7.54 €3,129
27. Nov 19 Buy Lorenzo Tallarigo Individual 26. Nov 19 26. Nov 19 470 €6.63 €3,118
28. Oct 19 Buy Lorenzo Tallarigo Individual 28. Oct 19 28. Oct 19 472 €6.56 €3,097
25. Sep 19 Buy Lorenzo Tallarigo Individual 25. Sep 19 25. Sep 19 482 €6.26 €3,016
16. Sep 19 Buy Natalie Walter Individual 13. Sep 19 13. Sep 19 1,754 €6.37 €11,182
16. Sep 19 Buy Andrew John Heath Individual 13. Sep 19 13. Sep 19 5,000 €6.39 €31,661
16. Sep 19 Buy Vulpes Investment Management Private Ltd Company 13. Sep 19 13. Sep 19 10,000 €6.14 €61,389
13. Sep 19 Buy Vulpes Investment Management Private Ltd Company 12. Sep 19 12. Sep 19 17,953 €6.44 €115,685
13. Sep 19 Buy Stuart Henderson Individual 13. Sep 19 13. Sep 19 1,248 €6.26 €7,816
23. Aug 19 Buy Lorenzo Tallarigo Individual 23. Aug 19 23. Aug 19 427 €6.90 €2,945
25. Jul 19 Buy Lorenzo Tallarigo Individual 25. Jul 19 25. Jul 19 368 €8.17 €3,005
26. Jun 19 Buy Lorenzo Tallarigo Individual 26. Jun 19 26. Jun 19 370 €8.05 €2,979
23. May 19 Buy Lorenzo Tallarigo Individual 23. May 19 23. May 19 388 €7.82 €3,035
25. Apr 19 Buy Lorenzo Tallarigo Individual 25. Apr 19 25. Apr 19 379 €8.18 €3,100
23. Apr 19 Buy Andrew John Heath Individual 23. Apr 19 23. Apr 19 6,023 €7.77 €46,623
X
Management checks
We assess Oxford BioMedica's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Oxford BioMedica has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

OXOA News

Simply Wall St News

OXOA Company Info

Description

Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson’s disease, central nervous system disorders, and ophthalmology in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company’s proprietary products under development stage include OXB-202, which is in a Phase I/II trial preparation for the prevention of corneal graft rejection; OXB-302 that has completed pre-clinical development for use in the treatment of a range of cancers; and OXB-201, which completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. Its partnered products in development stage comprise AXO-Lenti-PD that is in a Phase I/II trial preparation for the treatment of Parkinson's disease; SAR 422459, which is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869 that is in Phase I/II trial for the treatment of Usher syndrome 1B. The company’s products in preclinical stage include OXB-204 and OXB-208 for the treatment of ophthalmology; and OXB-103 for the treatment of CNS disorders. Oxford BioMedica plc has partnerships with Novartis, Sanofi, Orchard Therapeutics, Bioverativ, Axovant Gene Therapies, Santen, the UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim, Imperial Innovations, and Microsoft. The company was founded in 1995 and is headquartered in Oxford, the United Kingdom.

Details
Name: Oxford BioMedica plc
OXOA
Exchange: DB
Founded: 1995
£475,692,674
76,907,779
Website: http://www.oxfordbiomedica.co.uk
Address: Oxford BioMedica plc
Windrush Court,
Transport Way,
Oxford,
Oxfordshire, OX4 6LT,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
LSE OXB Ordinary Shares London Stock Exchange GB GBP 16. Dec 1996
OTCPK OXBD.F Ordinary Shares Pink Sheets LLC US USD 16. Dec 1996
DB OXOA Ordinary Shares Deutsche Boerse AG DE EUR 16. Dec 1996
BATS-CHIXE OXBL Ordinary Shares BATS 'Chi-X Europe' GB GBP 16. Dec 1996
Number of employees
Current staff
Staff numbers
480
Oxford BioMedica employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 20:40
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/02
Last earnings filing: 2019/09/04
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.